Clinical trials with the parent compound
The parent compound was tested in phase 2 clinical trials many years ago involving more than 1000 patients with solid tumors. The clinical trials were open-label trials and cannot be used in a regulatory filing but do give an insight into the potential efficacy and safety of the compound and CellProtect was encouraged by the German regulatory agencies to pursue further development.
The clinical information on the parent compound remains largely unpublished.
The data can be discussed under confidentiality agreement.